Clinical TrialsSearch results
Number of results: 896
- Recruitment status
- Title of the study
- Health Condition
- Primary sponsor
- Date of registration
Other
- A Phase 2/3 Study of SYR-322 as an Add-on to a Sulfonylurea
- Type 2 diabetes mellitus
- Takeda Pharmaceutical Company Limited
- 2009-04-01
Recruiting
- A Phase 2/3, Open-label, Historical-controlled, Single-arm, Multicenter Studyto Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety ofRavulizumab in Children and Adolescents With Aquaporin-4 Antibody Positive(AQP4-Ab [+]) Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Neuromyelitis Optica Spectrum Disorder
- Wuebbenhorst Hiroaki
- 2022-08-09
Other
- A Phase 3 Study of High dose E0302 against Amyotrophic Lateral Sclerosis - Investigator Initiated Study ("Tsunagi" phase)
- Amyotrophic Lateral Sclerosis
- Endo Akira
- 2024-08-22
Completed
- A Phase 3 Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis
- Hyperphosphatemia Patients on Hemodialysis
- Kinoshita Jun
- 2021-03-04
Recruiting
- A Phase 3 study of S-217622 targeting non-hospitalized participants
- COVID-19
- Portsmouth Simon
- 2022-10-01
Other
- A phase 3 study of S-812217 in combination with an antidepressant in patients with major depressive disorder
- depression
- Gomez Juan Carlos
- 2022-10-28
Other
- A Phase 3 Study of TAS-120 (Futibatinib) in Patients with intrahepatic Cholangiocarcinoma
- Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
- Zhang Yan
- 2020-11-09
Other
- A Phase 3 trial of perioperative pembrolizumab or enfortumab vedotin in combination with pembrolizumab in participants who are cisplatin-ineligible or decline cisplatin with Muscle-Invasive Bladder Cancer
- Muscle-invasive Bladder Cancer
- Tanaka Yoshiyuki
- 2023-03-03
Recruiting
- A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD
- Atopic Dermatitis
- Jain Neal
- 2023-07-01
Recruiting
- A Phase 3, Open-label Study Assessing Self-administered Rocatinlimab (AMG 451) in Subjects With Moderate-to-severe AD
- Atopic Dermatitis
- Chen Sarah
- 2024-04-23